Date:2/19/2009

on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, while the Company has begun shipment of ABthrax to the U.S. Strategic National Stockpile, the Company will continue to face risks related to acceptance of future shipments and FDA's approval of the Company's Biologics License Application for ABthrax, if and when it is submitted. If the Company is unable to meet requirements associated with the ABthrax contract, future revenues from the sale of ABthrax to the U.S. Government will not occur. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

'/>"/>

SOURCE Human Genome Sciences, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related biology technology :

1. Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes
2. China Biologic Products High-Purity Human Albumin Research and Development Project to be Listed in the National Torch Plan
3. 14th Annual Wharton Health Care Business Conference to Feature CEOs from WebMD, McKesson, Humana and Given Imaging
4. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
5. ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Neural Cells
6. Modigene Awarded Second-Year Grant by Israeli Government to Support Development of Its Longer-Acting Human Growth Hormone
7. Victhom Human Bionics Neurobionix Division receives ISO 13485:2003 Certification for its Design Control System
8. MultiVu Video Feed: Geron Receives FDA Clearance to Begin Worlds First Human Clinical Trial of Embryonic Stem Cell-Based Therapy
9. Rules-Based Medicine, Inc. Launches Human Kidney Damage Biomarker Panel
10. Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C
11. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Conference